The ICS/Formoterol Reliever Therapy Regimen in Asthma: A Review
Authors:
Open Access
- 10 January 2023
- journal article
- review article
- Published by Elsevier in Journal of Allergy and Clinical Immunology
- Vol. 11 (3) , 762-772.e1
Abstract
No abstract availableKeywords
Funding Information
- Genentech
- Health Research Council of New Zealand
- AstraZeneca
This publication has 67 references indexed in Scilit:
- Evaluation of Budesonide-Formoterol for Maintenance and Reliever Therapy Among Patients With Poorly Controlled AsthmaJAMA Network Open, 2022
- Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthmaCochrane Database of Systematic Reviews, 2020
- Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent AsthmaJAMA, 2018
- Addition of long-acting beta2-agonists to inhaled corticosteroids for chronic asthma in childrenCochrane Database of Systematic Reviews, 2015
- Combination corticosteroid/β-agonist inhaler as reliever therapy: A solution for intermittent and mild asthma?Journal of Allergy and Clinical Immunology, 2014
- Comparison of Physician-, Biomarker-, and Symptom-Based Strategies for Adjustment of Inhaled Corticosteroid Therapy in Adults With AsthmaJAMA, 2012
- AdherenceClinics in Chest Medicine, 2012
- Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherenceJournal of Allergy and Clinical Immunology, 2011
- The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trialJournal of Allergy and Clinical Immunology, 2007
- The circumstances preceding death from asthma in young people in 1968 to 1969Respiratory Medicine, 1971